BING-NEEL SYNDROME: ILLUSTRATIVE CASES AND COMPREHENSIVE REVIEW OF THE LITERATURE
Main Article Content
Keywords
Bing-Neel Syndrome, Waldenström’s Macroglobulinemia, Central Nervous System
Abstract
The Bing-Neel syndrome is a rare neurological complication of Waldenström’s Macroglobulinemia which results from a direct involvement of central nervous system by malignant lymphoplasmacytic cells. The clinical suspicion of Bing-Neel syndrome may be difficult because neurologic symptoms are heterogeneous, non specific and sometimes underhand. A definitive diagnosis of Bing-Neel syndrome can be confidently made using brain and spinal cord magnetic resonance imaging as well as histopathology and/or cerebrospinal fluid analysis to confirm the neoplastic infiltration of central nervous system. The detection in the cerebrospinal fluid of patients with Bing-Neel syndrome of the MYD88 (L265P) somatic mutation, which is highly recurrent in Waldenström’s Macroglobulinemia, revealed useful for the diagnosis and monitoring of central nervous system involvement. Despite recommendations recently published, there is still no clear consensus on treatment of Bing-Neel syndrome, which includes systemic immunochemotherapy, intrathecal chemotherapy and brain irradiation as possible options. Ibrutinib, a Bruton kinase inhibitor highly active in patients with Waldenström’s Macroglobulinemia, has been recently added to the therapeutic armamentarium of Bing-Neel syndrome due to its ability to pass the blood-brain barrier. However, prospective clinical trials are eagerly awaited with the aim to define the optimal treatment strategy.
Here we describe four illustrative cases of Bing-Neel syndrome diagnosed and treated at our Institution and review the literature on this topic.
Downloads
Abstract 2864
PDF Downloads 1044
HTML Downloads 1114
References
Treon SP. How I treat Waldenstrom Macroglobulinemia. Blood 2015; 126: 721-732
Malkani RG, Tallman M, Gottardi-Littel N, et al. Bing Neel syndrome: an illustrative case and a comprehensive review of the published literature. J Neuroncol 2010, 96(3): 301-312
Bing J, von Neel A. Two cases of hyperglobulinaemia with affection of the central nervous system on a toxi-infectious basis. Acta Med Scand 1936; 88: 492-506
Simon L, Fitsiori A, Lemal R et al, Bing-Neel syndrome, a rare complication of Waldenström’s Macroglobulinemia: analysis of 44 cases and review of literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica 2015; 100 (12): 1587-1594
Castillo JJ, D’Sa S, Lunn MP, et al. Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol 2016; 172: 709–715
Minnema MC, Kimby E, D’Sa S et al, Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 2017; 102(1):43-51
Varettoni M, Marchioni E, Bonfichi M, et al. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenstrom’s Macroglobulinemia complicated by Bing-Neel syndrome. Am J Hematol 2015; 90: E152-E153
Cabannes-Hamy A, Lemal R, Goldwirt L, et al. Efficacy of Ibrutinib in the treatment of Bing-Neel syndrome. Am J Hematol, 2016; 91(3): E17-19
Mason C, Savona S, Rini JN, et al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol, 2016; doi:10.1111/bjh.14218
Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012; 119(10): 2205-2208
Stork AC, van der Pol WL, Franssen H, et al. Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. J Neurol 2014; 261(7): 1398-1404
Grewal JS, Brar JK, Sahijdak WM et al. Bing Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis and treatment options. Clin Lymphoma Myeloma 2009; 9(6): 462-466
Gupta N, Gupta S, Al Ustwani O, et al. Bing-Neel syndrome in a patient with Waldenstrom's macroglobulinemia: a challenging diagnosis in the face of normal brain imaging. CNS Neurosci Ther 2014;20(10): 945-946
Zetterberg. Patognomonic cerebrospinal fluid findings in Bing-Neel syndrome. J Neurooncol 2011; 104 (2): 615
Hughes MS, Atkins EJ, Cestari DM et al. Isolated optic nerve, chiasm, and tract involvement in Bing Neel syndrome. J Neuroophtalmol 2014; 34(4):340-345
Stacy RC, Jakobiec FA, Hochberg FH, et al. Orbital involvement in Bing Neel syndrome. J Neuroophtalmol, 2010; 30(3): 255-259
Treon SP, Xu L, Yang G et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012; 367: 826-833
Poulain S, Boyle EM, Roumier C, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol 2014; 167: 506-513
Montesinos-Rongen M, Godlewska E, Brunn A, et al. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011 Dec; 122(6):791-792
Elliott MA, Letendre L, Li CY, et al. Chronic lymphocytic leukemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br J Haematol 1999; 104: 689-694
Knop S, Herrlinger U, Ernemann U, et al. Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46: 1593-1598
Vos JM, Kersten MJ, Kraan W et al. Effective treatment of Bing Neel syndrome with oral fludarabine: a case series of four consecutive patients. Br J Haematol 2016; 172 (3): 461-464
Bernard S, Goldwirt L, Amorim S et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood 2015; 126(14):1695-1698
Saad S, Wang TJ. Neurocognitive deficits after radiation therapy for brain malignancies. Am J Clin Oncol 2015; 38(6):634-640
Tallet AV, Azria D, Barlesi F et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 2012; 7:77